Degenerative disc disease is a common structural finding in patients with chronic low back pain, but disc degeneration does not always mean the disc is the main pain generator. Intervertebral disc degeneration involves changes in disc hydration, extracellular matrix composition, nucleus pulposus cell activity, annular integrity, inflammation, and mechanical loading. Umbilical cord-derived mesenchymal stem cell therapy, or UC-MSC stem cell therapy, is being studied as a regenerative approach because of its potential paracrine, anti-inflammatory, trophic, and matrix-supportive signaling effects. However, UC-MSC stem cell therapy should not be presented as a guaranteed cure for back pain or a proven method to rebuild severely collapsed discs. This article reviews the clinical rationale, mechanism, patient selection, safety considerations, and limitations of UC-MSC stem cell therapy for degenerative disc disease and discogenic low back pain.
Introduction
Low back pain is one of the most common musculoskeletal complaints worldwide. In clinical practice, the cause of back pain may include muscle strain, facet joint arthritis, sacroiliac joint dysfunction, spinal stenosis, disc herniation, annular tear, nerve compression, deformity, fracture, inflammatory disease, or degenerative disc disease.
Degenerative disc disease, or DDD, refers to age-related or injury-related changes in the intervertebral discs. These discs function as shock-absorbing structures between the vertebrae. Each disc contains an inner nucleus pulposus, an outer annulus fibrosus, and cartilage endplates that help with nutrient exchange.
When degeneration progresses, the disc may lose hydration, become less elastic, develop annular fissures, reduce in height, and contribute to altered spinal mechanics. In selected patients, these changes may produce discogenic low back pain.
The key clinical issue is diagnosis. Not every abnormal MRI finding causes pain. Many people have degenerative changes on imaging without severe symptoms. Therefore, regenerative therapy should be considered only when the disc is reasonably identified as a pain source.
Pathophysiology of Intervertebral Disc Degeneration
The intervertebral disc is a low-vascular structure with limited intrinsic repair capacity. Disc cells depend on diffusion through the endplate for nutrients and oxygen. With aging, mechanical overload, smoking, metabolic stress, injury, or genetic factors, the disc environment may become less favorable for cell survival and matrix maintenance.
Degeneration is associated with reduced proteoglycan content, decreased water retention, inflammatory mediator release, extracellular matrix breakdown, and increased mechanical stress on surrounding spinal structures. As the disc loses height, load may shift to the facet joints, ligaments, and adjacent vertebral segments.
This process is not purely mechanical. Inflammatory cytokines, oxidative stress, and cellular senescence may contribute to pain and progressive tissue dysfunction. These biological features explain why regenerative medicine has become an area of interest in disc degeneration research.
Figure 1: Biological and Mechanical Changes in Intervertebral Disc Degeneration
What Are UC-MSCs?
UC-MSC stem cell therapy are mesenchymal stem cells derived from umbilical cord tissue, commonly from Wharton’s jelly. They are not embryonic stem cells. In regenerative medicine, UC-MSC stem cell therapy are mainly studied for their paracrine signaling effects rather than direct tissue replacement.
Paracrine signaling refers to the release of growth factors, cytokines, extracellular vesicles, and other biological molecules that may influence inflammation, cell survival, extracellular matrix metabolism, angiogenic signaling, and tissue repair pathways.
For degenerative disc disease, UC-MSC stem cell therapy should not be explained as cells that automatically become new disc tissue after injection. A more scientifically responsible explanation is that UC-MSC stem cell therapy may help support the disc microenvironment through anti-inflammatory, trophic, and matrix-supportive signaling.
Rationale for UC-MSC Therapy in Discogenic Back Pain
The biological rationale for UC-MSC therapy in degenerative disc disease includes several proposed mechanisms.
First, UC-MSC-derived signals may help modulate inflammatory activity inside or around the degenerated disc. Inflammation is one contributor to discogenic pain and may influence nerve irritation and matrix degradation.
Second, MSC signaling may support nucleus pulposus cell survival and extracellular matrix-related pathways. The nucleus pulposus depends on proteoglycans and water retention to maintain disc function.
Third, UC-MSC stem cell therapy may influence oxidative stress and cellular stress responses, both of which are relevant in a low-nutrient disc environment.
Fourth, regenerative signaling may support local tissue communication, although this should not be interpreted as guaranteed structural restoration.
The goal is therefore not simply “disc regrowth.” A more realistic goal is biological support of the disc environment in selected patients with discogenic low back pain.
Intradiscal Delivery and Treatment Planning
For discogenic low back pain, stem cell therapy is often discussed through intradiscal injection, where cells are delivered directly into the affected disc under image guidance. Image guidance is important because the disc is a deep spinal structure and injection accuracy affects both safety and treatment quality.
Treatment planning should include MRI review, symptom correlation, neurological examination, and exclusion of other major pain sources. If pain is mainly caused by severe spinal stenosis, unstable spondylolisthesis, advanced facet arthritis, infection, fracture, tumor, or major nerve compression, intradiscal regenerative therapy may not be appropriate.
The route, dose, and number of treated levels should be determined by medical assessment rather than by a generic package.
Patient Selection
Patient selection is central to clinical reasoning. A better candidate may be a patient with chronic discogenic low back pain, MRI-confirmed disc degeneration, preserved enough disc structure, stable neurological status, and failure of conservative care such as physical therapy, activity modification, medication, or guided pain management.
A less suitable candidate may have severe disc collapse, major spinal instability, advanced deformity, severe canal stenosis, progressive neurological deficit, active infection, cancer-related spine disease, acute fracture, or urgent surgical indications.
Patients should also be evaluated for metabolic and lifestyle factors that may affect spine health, including smoking, diabetes, weight, activity level, muscle conditioning, sleep, and inflammatory status.
Safety and Quality Considerations
UC-MSC stem cell therapy for spine conditions requires careful safety standards. Patients should ask about cell source, donor screening, infectious disease testing, sterility testing, viability testing, endotoxin testing, dose calculation, transport conditions, and physician supervision.
For intradiscal procedures, additional procedural risks must be discussed, including post-injection pain flare, infection, discitis, bleeding, nerve irritation, and worsening symptoms. Although serious complications are uncommon when procedures are performed properly, they cannot be ignored.
A regenerative spine program should include informed consent, imaging review, sterile technique, image-guided delivery, and post-procedure follow-up.
Limitations of Current Evidence
Stem cell therapy for degenerative disc disease remains an evolving field. Early clinical studies and reviews suggest potential improvement in pain and function in selected patients, but evidence is still not uniform. Differences in cell source, dose, culture method, delivery route, patient selection, disc grade, follow-up duration, and outcome measures make direct comparison difficult.
Structural MRI improvement should also be interpreted carefully. Pain improvement does not always match imaging change, and imaging change does not always prove clinically meaningful regeneration.
Therefore, UC-MSC stem cell therapy should not be described as a proven alternative to surgery for all patients. It may be considered as a supportive regenerative option for selected cases, especially where discogenic pain is suspected and major surgical indications are absent.
Conclusion
UC-MSC stem cell therapy for degenerative disc disease is a developing area of regenerative spine medicine. The scientific rationale is based on paracrine signaling, inflammation modulation, cell-survival support, and extracellular matrix-related pathways within the degenerative disc environment.
However, degenerative disc disease is clinically complex. MRI findings must be matched with symptoms, physical examination, and functional limitations. UC-MSC stem cell therapy should not be promised to rebuild severely collapsed discs, cure chronic back pain, reverse all degeneration, or replace surgery when surgery is clearly indicated.
The central clinical question is not whether stem cells can “regenerate the spine.” A more appropriate question is whether the patient has discogenic low back pain with enough remaining disc structure and a suitable biological target for regenerative support.
When guided by imaging, diagnosis, patient selection, cell quality, image-guided technique, safety controls, and realistic expectations, UC-MSC stem cell therapy can be discussed in a more scientifically responsible way for patients seeking regenerative spine care in Thailand.